<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437356</url>
  </required_header>
  <id_info>
    <org_study_id>8049201834825</org_study_id>
    <nct_id>NCT03437356</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation</brief_title>
  <acronym>POWDER-AF2</acronym>
  <official_title>Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the POWDER 1 study, paroxysmal atrial fibrillation (AF) patients undergoing conventional&#xD;
      contact force (CF)-guided PVI were investigated. Patients were randomized between continuing&#xD;
      previously ineffective antiarrhythmic drug therapy (ADT) or stopping ADT at the end of the&#xD;
      blanking period. This trial, showed an added value of ADT after ablation (in support of&#xD;
      'hybrid rhythm control' as an alternative treatment strategy for AF in some patients).&#xD;
&#xD;
      In the POWDER 2 trial, an analogue study in persistent AF patients will be performed. All&#xD;
      patients will undergo ablation index (AI)- and IL distance (ILD)-guided PVI (just like in&#xD;
      VISTAX trial) and continue previously ineffective ADT during the blanking period. 'PVI only'&#xD;
      was chosen as the ablation strategy according to the STAR AF trial findings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: In real-life, ADT is often continued after catheter ablation for persistent AF.&#xD;
      No study investigated whether ADT continued beyond the blanking period reduces recurrence&#xD;
      after a first ablation for persistent AF.&#xD;
&#xD;
      Purpose: The aim of this trial is to investigate whether continued ADT (ADT ON) reduces&#xD;
      recurrence of atrial tachyarrhythmia (ATA) in the first year after contact-force guided PVI&#xD;
      for persistent AF.&#xD;
&#xD;
      Hypothesis: Continued use of ADT beyond the blanking period reduces recurrence of ATA in the&#xD;
      first year after PVI .&#xD;
&#xD;
      Eligibility: Subjects that are planned for catheter ablation for persistent AF.&#xD;
&#xD;
      Inclusion: Symptomatic persistent AF resistant to ongoing or prior ADT (failed ADT).&#xD;
      Persistent AF is defined as the presence of any prior AF episode ≥7 days.&#xD;
&#xD;
      Exclusion: Any prior AF episode ≥12 months, any recurrence of AF &lt;3 days after cardioversion.&#xD;
&#xD;
      Echo criteria: advanced valvular heart disease, left atrium (LA) volume &gt;37ml/m2, left&#xD;
      ventricle (LV) ejection fraction &lt;35% (except if suspected tachycardiomyopathy), septal&#xD;
      diameter &gt;15mm, Life expectancy &lt;1 year, BMI &gt;35.&#xD;
&#xD;
      Trial design: This is a prospective, multi-center, randomized (1:1), open label, blinded&#xD;
      endpoint study (PROBE). Eligible subjects who sign the study informed consent form at the&#xD;
      time of procedural planning will be randomized into one of two study arms: In the ADT off arm&#xD;
      (ADT OFF), ADT will be stopped at 3 months after the first procedure. In the ADT ON arm, ADT&#xD;
      will be continued at 3 months until 1 year follow up (FU).&#xD;
&#xD;
      First ablation and blanking: In both arms, catheter ablation will consist of 'CLOSE'-guided&#xD;
      PVI only (abl index and interlesion distance). High-density voltage mapping will be performed&#xD;
      during sinus rhythm. After ablation, ADT is continued/restarted during the 3-month blanking&#xD;
      period (except for amiodarone). During the blanking period cardioversions are allowed. At the&#xD;
      3-month visit, all patients will be cardioverted if ATA is present.&#xD;
&#xD;
      Repeat ablation strategy: In case of recurrence of ATA's after 3 months, a repeat ablation is&#xD;
      recommended. Depending on the reconnection status of the pulmonary veins (PV), repeat&#xD;
      ablation will consist of either PVI only or a patient-tailored ablation approach (antral&#xD;
      isolation, superior vena cava (SVC) isolation, isolation of low voltage, linear lesions).&#xD;
      Patients stay on the ADT ON or ADT OFF arm.&#xD;
&#xD;
      Primary Endpoint: Any documented ATA (atrial fibrillation, AF, atrial tachycardia, AT, atrial&#xD;
      flutter, AFL) lasting &gt;30s from 3 months through 12 month follow-up after the first&#xD;
      procedure.&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
      ATA recurrence in patients with early peristent AF (defined as AF ≤3 months) Incidence of&#xD;
      repeat ablation Unscheduled visits and hospitalisation ADT or ablation related adverse events&#xD;
      QOL and symptoms Outcome after repeat ablation&#xD;
&#xD;
      Sample size: In the ADT OFF group ATA recurrence after a first PVI is expected to be 50%. ADT&#xD;
      are expected to reduce ATA recurrence to 30%. Given power of 80% and α of 0.05 up to 200&#xD;
      subjects need be enrolled in this study (20 per center)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any documented AF/atrial tachycardia (AT)/atrial flutter (AFL) recurrence</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Recurrence will be considered as AF/AT/AF lasting &gt;30 seconds, as measured by 1-day Holter monitoring at 6 month after PVI, 7-day Holter (screening for AF between 48 hours and 7 days) at 12 months after PVI, and by any standard of care or unscheduled arrhythmia monitoring documentation throughout the follow-up (ie. from 3 to 12 months after PVI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF/atrial tachycardia (AT)/atrial flutter (AFL) recurrence in early persistent AF</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of recurrence of early persistent AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of repeat ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled health care visits and hospitalizations</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Incidence of unscheduled health care visits and/or hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADT-related adverse events</measure>
    <time_frame>From 3 to 12 months after PVI</time_frame>
    <description>Adverse events related to continuation of ADT in the ON group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation-related adverse events</measure>
    <time_frame>From 0 to 12 months after ablation</time_frame>
    <description>Adverse events related to ablation in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment (SF-36)</measure>
    <time_frame>At Enrollment, and at 3 months, 6 months, and 12 months after ablation</time_frame>
    <description>At each scheduled visit, the patients will fill the SF-36 questionnaire for the assessment of Quality of life before and after ablation in both groups. SF-36 individual scores (0-100) will be converted into z-scores as standardized combined scores (mean 50, standard deviation 10) for US population (Ware et al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF symptom scores</measure>
    <time_frame>At Enrollment, and at 3 months, 6 months, and 12 months after ablation</time_frame>
    <description>At each scheduled visit, the patients will fill AF checklist: 16 questions of AF severity (score = minimum 16, maximum 48) and 16 questions of AF frequency (score = minimum 16, maximum 64) for qualitative assessment of AF symptoms before and after ablation in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of recurrence</measure>
    <time_frame>At baseline</time_frame>
    <description>Any conventional clinical characteristics acquired at baseline that could predict recurrence of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome after repeat ablation</measure>
    <time_frame>From 3 to 12 months after first PVI</time_frame>
    <description>Incidence of AF recurrence after multiple ablation procedures (if applicable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>ADT ON Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT OFF Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary vein isolation using CLOSE protocol</intervention_name>
    <description>'CLOSE' protocol: Ablation index &gt; 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index &gt; 550 at the anterior wall, and inter-lesion distance &lt; 6.0mm</description>
    <arm_group_label>ADT OFF Group</arm_group_label>
    <arm_group_label>ADT ON Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug therapy (ADT)</intervention_name>
    <description>During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.&#xD;
Preferred dosages:&#xD;
Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or &lt;70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men &lt; 70 years, Cr &lt;1.5mg/dl, &gt;70kg, except 80 mg OD if female &gt;70 years or Cr &gt;1.2mg/dl&#xD;
In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT.</description>
    <arm_group_label>ADT ON Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with symptomatic persistent AF, resistant to ongoing or prior ADT (failed ADT)&#xD;
             Patients is considered to have persistent AF if the patient has suffered any prior AF&#xD;
             episode ≥7 days (ESC 2016 guidelines).&#xD;
&#xD;
          2. Before PVI, there was at least one episode of persistent AF in the last year.&#xD;
&#xD;
          3. Signed Patient Informed Consent Form.&#xD;
&#xD;
          4. Age 18 years or older.&#xD;
&#xD;
          5. Able and willing to comply with all follow-up testing and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not willing or not suited to take any class IC or III ADT.&#xD;
&#xD;
          2. Any prior AF episode ≥12 months, or any recurrence of AF &lt;3 days after cardioversion.&#xD;
&#xD;
          3. Presence of structural heart disease on echo criteria:&#xD;
&#xD;
             severe valvular heart disease; LA diameter &gt;50mm; LV ejection fraction &lt;35% (except if&#xD;
             suspected tachycardiomyopathy); septal diameter &gt;15mm&#xD;
&#xD;
          4. BMI &gt;35&#xD;
&#xD;
          5. Recent (&lt;3 months) coronary artery bypass grafting (CABG), myocardial infarction,&#xD;
             cerebral vascular accident (CVA), uncontrolled heart failure or angina&#xD;
&#xD;
          6. Active illness or systemic infection or sepsis&#xD;
&#xD;
          7. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          8. Awaiting cardiac transplantation or other cardiac surgery&#xD;
&#xD;
          9. Documented left atrial thrombus or atrial myxoma on imaging&#xD;
&#xD;
         10. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         11. Enrollment in any other study evaluating another device or drug&#xD;
&#xD;
         12. Women with childbearing potential&#xD;
&#xD;
         13. Life expectancy less than 12 months&#xD;
&#xD;
         14. Contraindication for catheter ablation (intramural thrombus, tumor or other&#xD;
             abnormality that precludes catheter introduction, contraindication to anticoagulation&#xD;
             therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattias Duytschaever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A Sint -Jan Bruges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Hospital</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Mattias Duytschaever</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>antiarrhythmic drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

